文献速递类风湿关节炎

偏好表型促进类风湿关节炎共享决策

Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2017-12-15

本研究采用联合分析调查测量类风湿关节炎患者对三联治疗、生物制剂和Janus激酶(JAK)抑制剂的偏好,共1273名参与者完成调查,通过潜在类别分析识别出五组偏好表型,最大组(38.4%)最受药物费用影响,结果强调患者价值观的变异性及共享决策实施达标治疗的重要性。

要点

  • 联合分析调查识别出5种偏好表型,最大组(38.4%)最受药物费用影响。
  • 25.8%组最受困扰性副作用风险影响,11.2%组最关注极罕见副作用风险。
  • 6.6%组强烈偏好口服而非肠外给药,18.0%组同等受起效时间和严重感染风险影响。

核心结论

  • 类风湿关节炎患者的治疗偏好可被测量并归纳为不同的表型。
  • 研究结果强调患者价值观存在变异性,采用共享决策方法实施达标治疗具有重要性。

研究设计与样本

  • 研究开发联合分析调查以测量类风湿关节炎患者对三联治疗、生物制剂和Janus激酶(JAK)抑制剂的偏好。
  • 调查包含七项属性:给药方式、起效时间、困扰性副作用、严重感染、极罕见副作用、信息量和费用。
  • 每个选择集(n=12)包含三个假设方案,共1273名参与者完成调查,采用潜在类别分析识别偏好表型。

主要发现

  • 基于赤池信息准则和贝叶斯信息准则值逐步降低,选择五组解决方案。
  • 最大组(第3组:38.4%)最强烈受药物费用影响。
  • 次大组(第1组:25.8%)最强烈受困扰性副作用风险影响。
  • 第2组(11.2%)同样规避风险,但最关注极罕见副作用风险。
  • 第4组(6.6%)强烈偏好口服而非肠外给药;第5组(18.0%)最强烈且同等地受起效时间和严重感染风险影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Implementing treat-to-target (TTT) strategies requires that patients with rheumatoid arthritis (RA) and their rheumatologists decide on how best to escalate care when indicated. The objective of this study was to develop preference phenotypes to facilitate shared decision-making at the point of care for patients failing methotrexate monotherapy. METHODS: We developed a conjoint analysis survey to measure the preferences of patient with RA for triple therapy, biologics and Janus kinase (JAK) inhibitors. The survey included seven attributes: administration, onset, bothersome side effects, serious infection, very rare side effects, amount of information and cost. Each choice set (n=12) included three hypothetical profiles. Preference phenotypes were identified by applying latent class analysis to the conjoint data. RESULTS: 1273 participants completed the survey. A five-group solution was chosen based on progressively lower values of the Akaike and Bayesian information criteria. Members of the largest group (group 3: 38.4%) were most strongly impacted by the cost of the medication. The next largest group (group 1: 25.8%) was most strongly influenced by the risk of bothersome side effects. Members of group 2 (11.2%) were also risk averse, but were most concerned with the risk of very rare side effects. Group 4 (6.6%) strongly preferred oral over parenteral medications. Members of group 5 (18.0%) were most strongly and equally influenced by onset of action and the risk of serious infections. CONCLUSIONS: Treatment preferences of patients with RA can be measured and represented by distinct phenotypes. Our results underscore the variability in patients' values and the importance of using a shared decision-making approach to implement TTT.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Fraenkel L, Nowell WB, Michel G, et al. Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 29247126. doi:10.1136/annrheumdis-2017-212407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。